# Title
Metabolism O
and O
drug O
interactions O
of O
3-hydroxy-3-methylglutaryl B-Gene
coenzyme I-Gene
A I-Gene
reductase I-Gene
inhibitors O
in O
transplant O
patients: B-Species
are O
the O
statins O
mechanistically O
similar? O

# Abstract
3-Hydroxy-3-methylglutaryl B-Gene
coenzyme I-Gene
A I-Gene
reductase I-Gene
(EC O
1.1.1.88) O
inhibitors O
are O
the O
most O
effective O
drugs O
to O
lower O
cholesterol B-Chemical
in O
transplant O
patients. B-Species
However, O
immunosuppressants O
and O
several O
other O
drugs O
used O
after O
organ O
transplantation O
are O
cytochrome O
P4503A B-ProteinMutation
(CYP3A, B-Gene
EC O
1.14.14.1) O
substrates. O
Pharmacokinetic O
interaction O
with O
some O
of O
the O
3-hydroxy-3-methylglutaryl B-Gene
coenzyme I-Gene
A I-Gene
reductase I-Gene
inhibitors, O
specifically O
lovastatin B-Chemical
and O
simvastatin, B-Chemical
leads O
to O
an O
increased O
incidence O
of O
muscle B-Disease
skeletal I-Disease
toxicity I-Disease
in O
transplant O
patients. B-Species
It O
is O
our O
objective O
to O
review O
the O
role O
of O
drug O
metabolism O
and O
drug O
interactions O
of O
lovastatin, B-Chemical
simvastatin, B-Chemical
pravastatin, B-Chemical
fluvastatin, B-Chemical
atorvastatin, B-Chemical
and O
cerivastatin. B-Chemical
In O
the O
treatment O
of O
transplant O
patients, B-Species
from O
a O
drug O
interaction O
perspective, O
pravastatin, B-Chemical
which O
is O
not O
significantly O
metabolized O
by O
CYP O
enzymes, O
and O
fluvastatin, B-Chemical
presumably O
a O
CYP2C9 B-Gene
substrate, O
compare O
favorably O
with O
the O
other O
statins O
for O
which O
the O
major O
metabolic O
pathways O
are O
catalyzed O
by O
CYP3A. B-Gene